Vernon Rogers
About Vernon Rogers
Vernon Rogers is Executive Vice President of Sales and Marketing at Aehr Test Systems; he joined in October 2018 and was listed among executive officers in the 2025 proxy (age 58) . He holds a B.S. in Electrical Engineering from North Dakota State University and has spent over two decades in senior sales, marketing and operations roles across semiconductor test and system-level test markets . Company performance context during his tenure: Aehr’s total shareholder return (TSR) index (fixed $100 base) moved from 394 (FY2023) to 512 (FY2024) and then 114 (FY2025), with net income of $14.6M (FY2023), $33.2M (FY2024), and a $(3.9)M loss (FY2025) .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Global Equipment Services (later acquired by Averna) | Head of Sales and Marketing | Not disclosed | Led sales/marketing; foundation for subsequent EVP Sales & Marketing role at Aehr . |
| LitePoint (acquired by Teradyne) | Senior sales/marketing roles | Not disclosed | Built multi-channel sales distribution and support in wireless test solutions . |
| Credence Systems (acquired by Xcerra) | Senior sales/marketing roles | Not disclosed | Semiconductor automated test equipment sales leadership . |
| NPTest (acquired by Credence) | Senior sales/marketing roles | Not disclosed | Semiconductor test equipment sales leadership . |
| Schlumberger Automated Test Equipment | Senior sales/marketing roles | Not disclosed | Nanoscale inspection/manufacturing/test solutions . |
| FlexStar Technology | Sales oversight | Not disclosed | HDD/SSD test and burn-in sales oversight . |
Fixed Compensation
- FY2024 base salary: $283,500 .
- FY2024 personal performance cash bonus: Target $90,000; paid $42,360 .
- FY2024 company performance cash bonus: Maximum opportunity up to 45.9% of base salary; paid $0 given results .
- FY2024 booking commissions: $48,773 under plan (0.1% on bookings ≤$120M; 2x rate above $120M) .
- FY2024 “All Other Compensation”: $67,595, including health/life/medical $46,624, ESOP contribution $8,771, auto allowance $12,000 .
Multi-year summary (amounts are those reported in Summary Compensation Table):
| Metric | FY2023 | FY2024 |
|---|---|---|
| Salary ($) | 268,561 | 296,311 |
| Stock Awards ($) | 216,000 | 184,698 |
| Non-Equity Incentive Comp ($) | 159,195 | 106,764 |
| All Other Compensation ($) | 66,640 | 67,595 |
| Total ($) | 710,396 | 655,368 |
Performance Compensation
- Booking commission plan evolution and realized commissions:
| Fiscal Year | Plan Mechanics | Realized Commissions ($) |
|---|---|---|
| FY2022 | 0.375% up to 100% of bookings quota; 0.75% above quota; paid upon revenue recognition month close | 320,377 |
| FY2023 | 0.108% existing customers; 0.216% new customers up to quota; double rates above quota; paid following month | 100,230 |
| FY2024 | 0.1% up to $120M bookings; double above $120M; paid following month | 48,773 |
- FY2024 annual bonus structure and outcomes:
| Component | Weighting/Opportunity | Target | Actual/Payout | Notes |
|---|---|---|---|---|
| Company performance bonus | Up to 45.9% of base salary | Not quantified in $ | 0 | No payout based on FY2024 results . |
| Personal performance bonus | Target cash | 90,000 | 42,360 | Discretionary, based on milestones . |
- Equity incentives (granted FY2024 cycle on Oct 27, 2023):
- Time-based RSUs: 6,200 RSUs vesting 1/16 quarterly over 4 years .
- Performance RSUs: 5,167 target RSUs vesting 100% upon achieving cumulative revenue target by May 31, 2026; service condition through achievement date .
Vesting conventions:
- RSUs generally vest 1/16 quarterly over 4 years; performance RSUs vest on goal achievement timelines per grant .
- Stock options (legacy grants) vest 1/48 monthly over 4 years; 10-year term .
Equity Ownership & Alignment
- Beneficial ownership trend:
| As-of Date | Shares Beneficially Owned | Ownership % |
|---|---|---|
| Aug 31, 2022 | 236,658 | <1% |
| Aug 25, 2023 | 158,685 | <1% |
| Aug 23, 2024 | 170,215 | <1% |
- Near-term vested/vesting breakdown (as of Aug 23, 2024): includes 150,468 options exercisable within 60 days and 3,653 RSUs vesting within 60 days .
- Hedging/pledging policy: Company prohibits hedging, short sales, and pledging/margin of company stock for insiders, including named executive officers .
- Clawback: Executive compensation is subject to a Dodd-Frank-compliant clawback policy adopted Aug 14, 2023 and filed as Exhibit 97.1 to the FY2025 Form 10-K .
Outstanding and Vesting Equity Detail (as of FY2024 year-end)
| Grant/Instrument | Status at 5/31/2024 | Shares/Options | Strike/Value | Vesting/Expiry |
|---|---|---|---|---|
| Stock options (10/23/2018) | Exercisable/Unexercisable | 110,283 / 185 | $2.03 | Exp. 10/23/2025 |
| Stock options (7/16/2019) | Exercisable (two tranches) | 15,262 / 24,738 | $1.635 | Exp. 7/16/2026 |
| RSUs (7/14/2020) | Unvested | 1,263 | $14,537 market value at $11.51 close | 1/16 quarterly |
| RSUs (7/13/2021) | Unvested | 4,199 | $48,330 market value | 1/16 quarterly |
| RSUs (7/14/2022) | Unvested (time-based) | 10,125 | $116,539 market value | 1/16 quarterly |
| RSUs (7/14/2022) | Unvested (perf.-linked tranche) | 5,061 | $58,252 market value | Perf. gate then 1/16 thereafter |
| RSUs (10/27/2023) | Unvested (time-based) | 5,425 | $62,442 market value | 1/16 quarterly |
| RSUs (10/27/2023) | Unvested (performance) | 5,167 target | $59,472 market value | 100% upon cumulative revenue target by 5/31/2026 |
Note: Market values use $11.51 closing price on 5/31/2024 as disclosed; vesting conventions per footnotes .
Employment Terms
- Role and start date: Joined Aehr as EVP Sales & Marketing in October 2018 .
- Change-in-control and severance (executed Aug 31, 2024 for Rogers):
- Qualifying termination during CIC period (3 months before to 12 months after CIC for Rogers): cash equal to 12 months base salary; 100% of target annual cash incentive; pro-rata target bonus for year of termination; full acceleration of time-based equity; performance equity deemed at the greater of target or expected attainment; up to 12 months Company-paid healthcare .
- Qualifying termination outside CIC: 6 months base salary; pro-rata target bonus; 6 months’ acceleration of unvested equity (performance at target); up to 6 months healthcare .
- Clawback: Covered under Company’s recovery policy (see above) .
- Non-compete/non-solicit: Not disclosed in proxy .
Performance & Track Record Context
| Fiscal Year | TSR Index (Fixed $100 Base) | Net Income ($000s) |
|---|---|---|
| 2023 | 394 | 14,557 |
| 2024 | 512 | 33,156 |
| 2025 | 114 | (3,910) |
- Compensation program emphasizes at-risk pay; commissions, performance cash, and performance RSUs tie earnings to bookings and cumulative revenue targets; prohibition on hedging/pledging supports alignment with shareholders .
- Legacy option grants carried expirations in Oct 2025 and July 2026, which historically can create exercise/settlement activity around expirations; the Company’s insider trading policy requires pre-clearance and prohibits hedging/pledging .
Compensation Structure Analysis
- Mix and evolution:
- Shift toward RSUs: FY2024 and FY2023 grants to Rogers were RSUs (time-based and performance-based); no new options to NEOs in FY2025; company notes RSUs predominant in recent cycles .
- Variable cash moderated with results: Booking commissions fell from $320,377 (FY2022) to $100,230 (FY2023) to $48,773 (FY2024) as plan mechanics and bookings evolved .
- Discretion retained: Personal performance bonuses paid despite no company performance bonus in FY2024 ($42,360 to Rogers) .
- Governance protections: Explicit prohibition on hedging/pledging and a compliant clawback policy mitigate misalignment and recoup risk .
Investment Implications
- Pay-for-performance linkage is tangible via commissions and performance RSUs on cumulative revenue, creating sensitivity to bookings momentum; declining commissions from FY2022 to FY2024 reflect tighter linkage to business trends .
- Retention risk appears moderate: Rogers has double-trigger CIC protection (12 months salary plus 100% target bonus and equity acceleration in a CIC termination window), and ongoing time-based/performance RSU vesting supports tenure incentives .
- Alignment signals are positive: strict prohibitions on hedging/pledging and an active clawback framework reduce adverse incentives; however, legacy option expirations (2025–2026) historically can create exercise-related trading windows that investors should watch around vesting/expiry cycles .